| scholarly article | Q13442814 |
| P50 | author | Raymond F. Schinazi | Q7298769 |
| Silvina Masciotra | Q112056633 | ||
| J Gerardo Garcia-Lerma | Q115633835 | ||
| David Delinsky | Q125272744 | ||
| Shoukat H Qari | Q55273601 | ||
| Walid Heneine | Q87716498 | ||
| P2093 | author name string | Thomas M Folks | |
| Jeffrey A Johnson | |||
| Mian-Er Cong | |||
| Wei Luo | |||
| Michael Monsour | |||
| Robert Janssen | |||
| Jonathan Lipscomb | |||
| Debra R Adams | |||
| Eddie Jackson | |||
| Caryn Kim | |||
| Ron A Otten | |||
| P2860 | cites work | Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract | Q22242981 |
| Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges | Q24812967 | ||
| Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection | Q28469067 | ||
| Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial | Q28469218 | ||
| Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations | Q28469253 | ||
| Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques | Q28775900 | ||
| Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection | Q29619099 | ||
| Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection | Q29619124 | ||
| Brief but efficient: acute HIV infection and the sexual transmission of HIV. | Q30341429 | ||
| Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus | Q30350983 | ||
| Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings | Q33299456 | ||
| Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients | Q33770032 | ||
| Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment | Q33782843 | ||
| Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). | Q33812016 | ||
| Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults | Q33983070 | ||
| Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV) | Q34060230 | ||
| Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase | Q34339657 | ||
| Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques | Q34716901 | ||
| 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques | Q35129347 | ||
| Perils at mucosal front lines for HIV and SIV and their hosts | Q36274922 | ||
| Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. | Q36793483 | ||
| Highly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaques | Q36954674 | ||
| Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection | Q37170172 | ||
| Man versus beast: pharmacokinetic scaling in mammals | Q38705508 | ||
| Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda | Q38881073 | ||
| High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa | Q38980790 | ||
| In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. | Q40270653 | ||
| Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine | Q42274867 | ||
| Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection | Q42642207 | ||
| Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection | Q43686445 | ||
| AIDS. Promote HIV chemoprophylaxis research, don't prevent it. | Q43702232 | ||
| Preexposure prophylaxis for HIV: unproven promise and potential pitfalls | Q44237731 | ||
| Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates | Q45194306 | ||
| Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges | Q45412452 | ||
| Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus | Q45415016 | ||
| Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion | Q45422914 | ||
| Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection | Q45754857 | ||
| Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. Transfusion Safety Study Group | Q45759924 | ||
| Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens | Q46595288 | ||
| Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor | Q46793130 | ||
| Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. | Q53781127 | ||
| Short Communication: A Rapid and Sensitive Real-Time PCR Assay for the K65R Drug Resistance Mutation in SIV Reverse Transcriptase | Q56792948 | ||
| Chemoprophylaxis of HIV Infection: Moving Forward with Caution | Q57207382 | ||
| Repetitive exposures with simian/human immunodeficiency viruses: strategy to study HIV pre-clinical interventions in non-human primates | Q64130395 | ||
| Delayed viral replication and CD4(+) T cell depletion in the rectosigmoid mucosa of macaques during primary rectal SIV infection | Q79330306 | ||
| Estimating the benefit of an HIV-1 vaccine that reduces viral load set point | Q79580562 | ||
| A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen | Q80210009 | ||
| P275 | copyright license | Creative Commons CC0 License | Q6938433 |
| P6216 | copyright status | copyrighted, dedicated to the public domain by copyright holder | Q88088423 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tenofovir | Q155954 |
| emtricitabine | Q422604 | ||
| prevention | Q1717246 | ||
| P304 | page(s) | e28 | |
| P577 | publication date | 2008-02-01 | |
| P1433 | published in | PLOS MEDICINE | Q1686921 |
| P1476 | title | Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir | |
| P478 | volume | 5 |
| Q36674455 | A discrete-time survival model with random effects for designing and analyzing repeated low-dose challenge experiments |
| Q36286901 | A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection |
| Q35667426 | A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. |
| Q34399535 | A polyvalent Clade B virus-like particle HIV vaccine combined with partially protective oral preexposure prophylaxis prevents simian-human immunodeficiency virus Infection in macaques and primes for virus-amplified immunity |
| Q46131427 | A preemptive strike against HIV. |
| Q30431343 | A review of nanotechnological approaches for the prophylaxis of HIV/AIDS. |
| Q35003539 | AIDS vaccines and preexposure prophylaxis: is synergy possible? |
| Q43881317 | AIDS: Drugs that prevent HIV infection |
| Q39686794 | Acceptability of an "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France |
| Q35102317 | Accuracy of highly sexually active gay and bisexual men's predictions of their daily likelihood of anal sex and its relevance for intermittent event-driven HIV pre-exposure prophylaxis |
| Q90022096 | Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report |
| Q41929948 | Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report |
| Q28533158 | Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa |
| Q33762924 | Advances in the Development of Microbicides for the Prevention of HIV Infection |
| Q36899773 | Advances in the prevention of heterosexual transmission of HIV/AIDS among women in the United States |
| Q34314648 | An intervention to support HIV preexposure prophylaxis adherence in HIV-serodiscordant couples in Uganda |
| Q95785042 | An intrinsic way of multiclassification of endogenous psychoses. A follow-through investigation/Budapest 2000/based upon Leonhard's classification |
| Q35572202 | Analysis of repeated low-dose challenge studies |
| Q26777022 | Animal and human mucosal tissue models to study HIV biomedical interventions: can we predict success? |
| Q38043556 | Animal models in virus research: their utility and limitations |
| Q28553127 | Antiretroviral Drug Activity in Macaques Infected during Pre-Exposure Prophylaxis Has a Transient Effect on Cell-Associated SHIV DNA Reservoirs |
| Q36873010 | Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis |
| Q24201955 | Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals |
| Q28292876 | Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial |
| Q28270788 | Antiretroviral prophylaxis for HIV prevention in heterosexual men and women |
| Q33318541 | Antiretroviral therapy for prevention of HIV infection: new clues from an animal model |
| Q35237188 | Antiretroviral-based HIV prevention strategies for women |
| Q36493442 | Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis |
| Q36964167 | Antiretrovirals and safer conception for HIV-serodiscordant couples |
| Q36597028 | Antiretrovirals to prevent HIV infection: pre- and postexposure prophylaxis |
| Q36553945 | Antiviral activity of retrocyclin RC-101, a candidate microbicide against cell-associated HIV-1 |
| Q36836680 | Antiviral agents and HIV prevention: controversies, conflicts, and consensus |
| Q39835907 | Beyond 2010: Gaps, Challenges, and Priorities for the Future of Preclinical HIV Preexposure Prophylaxis (PrEP): Summary of the October 20–21, 2009 Workshop |
| Q34805478 | Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward |
| Q33358267 | Can a topical microbicide prevent rectal HIV transmission? |
| Q28744206 | Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention |
| Q36281109 | Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239. |
| Q40597405 | Chemoprophylaxis With Oral Emtricitabine and Tenofovir Alafenamide Combination Protects Macaques From Rectal Simian/Human Immunodeficiency Virus Infection |
| Q36404961 | Chronic alcohol increases CD8+ T-cell immunosenescence in simian immunodeficiency virus-infected rhesus macaques |
| Q35541521 | Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery |
| Q39791215 | Clinical monitoring and correlates of nephropathy in SIV-infected macaques during high-dose antiretroviral therapy |
| Q37365377 | Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine |
| Q50116350 | Comprehensive Approaches to the Diagnosis and Treatment of HIV Infection in the Community: Can "Seek and Treat" Really Deliver? |
| Q41990298 | Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial |
| Q34421999 | Depot-medroxyprogesterone acetate does not reduce the prophylactic efficacy of emtricitabine and tenofovir disoproxil fumarate in macaques |
| Q57282336 | Determining the Roles that Club Drugs, Marijuana, and Heavy Drinking Play in PrEP Medication Adherence Among Gay and Bisexual Men: Implications for Treatment and Research |
| Q37845073 | Development of a rectal sexually transmitted infection--HIV coinfection model utilizing Chlamydia trachomatis and SHIVSF162p3. |
| Q56786248 | Discovery and Development of Tenofovir Disoproxil Fumarate |
| Q35473669 | Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men. |
| Q37209876 | Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course |
| Q35665851 | Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue |
| Q64137772 | Effects of gel volume on pharmacokinetics for vaginal and rectal applications of combination DuoGel-IQB4012, a dual chamber-dual drug HIV microbicide gel, in pigtailed macaques |
| Q54202671 | Efficacy of Vaginally Administered Gel Containing Emtricitabine and Tenofovir Against Repeated Rectal SHIV Exposures in Macaques. |
| Q35927290 | Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques |
| Q38659539 | Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study |
| Q38084940 | Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis |
| Q28477258 | Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand |
| Q33613769 | Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells |
| Q64103435 | Factors Associated With Sex-Related Pre-exposure Prophylaxis Adherence Among Men Who Have Sex With Men in New York City in HPTN 067 |
| Q28477780 | Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP) |
| Q39396606 | From modeling to morals: imagining the future of HIV PREP in Lesotho |
| Q64128826 | Generation and mucosal transmissibility of emtricitabine- and tenofovir-resistant SHIV162P3 mutants in macaques |
| Q37438644 | HIV PrEP Trials: The Road to Success |
| Q34674930 | HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial |
| Q34673978 | HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans |
| Q37505560 | HIV pre-exposure prophylaxis interest among female sex workers in Guangxi, China. |
| Q35794988 | HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model |
| Q28474086 | HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness |
| Q35765743 | HIV prevention by oral preexposure prophylaxis |
| Q33982161 | HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis |
| Q57207278 | HIV-1 Drug Resistance in Pre-exposure Prophylaxis Trials |
| Q34249966 | HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial |
| Q30378142 | HIV-prevention science at a crossroads: advances in reducing sexual risk. |
| Q36949755 | High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya |
| Q34110847 | High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis |
| Q37089865 | Humanized mouse models of HIV infection |
| Q47398084 | Hypo-osmolar Formulation of Tenofovir (TFV) Enema Promotes Uptake and Metabolism of TFV in Tissues, Leading to Prevention of SHIV/SIV Infection |
| Q28472968 | In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide |
| Q99622758 | Initiation, discontinuation, and restarting HIV pre-exposure prophylaxis: ongoing implementation strategies |
| Q89527088 | Interference with HIV infection of the first cell is essential for viral clearance at sub-optimal levels of drug inhibition |
| Q43108142 | Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection |
| Q37123335 | Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues |
| Q36299730 | Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis |
| Q35021555 | Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. |
| Q36290753 | Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase |
| Q41638108 | Microbicides for preventing sexually transmitted infections: Current status and strategies for preclinical evaluation of new candidates |
| Q35619584 | Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance |
| Q37661125 | Modelling the evolution of HIV-1 virulence in response to imperfect therapy and prophylaxis |
| Q37707803 | Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides. |
| Q36923075 | Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice |
| Q30412036 | Mucosal transmission of human immunodeficiency virus |
| Q35077568 | Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. |
| Q28072213 | New Biomedical Technologies and Strategies for Prevention of HIV and Other Sexually Transmitted Infections |
| Q79688333 | New biomedical strategies for HIV-1 prevention in women |
| Q35563416 | Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. |
| Q42225882 | Non-human primate models of hormonal contraception and HIV. |
| Q36669377 | Nondaily preexposure prophylaxis for HIV prevention |
| Q38692324 | On the Death Rate of Abortively Infected Cells: Estimation from Simian-Human Immunodeficiency Virus Infection |
| Q91557003 | On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial |
| Q35140303 | One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates |
| Q36409225 | Oral antiretroviral chemoprophylaxis: current status |
| Q33784852 | Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model |
| Q34680992 | Packaging PrEP to Prevent HIV: An Integrated Framework to Plan for Pre-Exposure Prophylaxis Implementation in Clinical Practice |
| Q27318212 | Parsimonious Determination of the Optimal Infectious Dose of a Pathogen for Nonhuman Primate Models |
| Q36353342 | Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission |
| Q37172505 | Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation |
| Q35432739 | Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques |
| Q37036412 | Pharmacokinetics of a multipurpose pod-intravaginal ring simultaneously delivering five drugs in an ovine model |
| Q36905431 | Pharmacologic opportunities for HIV prevention. |
| Q34481359 | Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection |
| Q60434051 | Pharmacology of Antiretrovirals in the Female Genital Tract for HIV Prevention |
| Q34036470 | Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities |
| Q42232018 | Postexposure protection of macaques from vaginal SHIV infection by topical integrase inhibitors |
| Q37369561 | Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments |
| Q43241737 | PrEP Implementation Science: State-of-the-Art and Research Agenda |
| Q35636514 | Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? |
| Q37637073 | Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherence |
| Q28539443 | Pre-exposure prophylaxis for the prevention of HIV infection in high risk populations: a meta-analysis of randomized controlled trials |
| Q35033732 | Pre-exposure prophylaxis of HIV: A right way to go or a long way to go? |
| Q37618260 | Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model |
| Q85063696 | Preefficacy Use and Sharing of Antiretroviral Medications to Prevent Sexually-Transmitted HIV Infection Among US Men Who Have Sex With Men |
| Q24612082 | Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men |
| Q26800989 | Preexposure Prophylaxis For HIV Prevention: What We Know and What We Still Need to Know for Implementation |
| Q34012348 | Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men |
| Q35717688 | Preexposure prophylaxis for HIV prevention |
| Q26825042 | Preexposure prophylaxis for HIV prevention: where have we been and where are we going? |
| Q34021932 | Preferences for daily or intermittent pre-exposure prophylaxis regimens and ability to anticipate sex among HIV uninfected members of Kenyan HIV serodiscordant couples |
| Q26828445 | Preventing HIV infection: pre-exposure and postexposure prophylaxis |
| Q36975282 | Prevention of the sexual transmission of HIV-1: preparing for success |
| Q34506545 | Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen |
| Q104468684 | Primary HIV-1 infection in users of pre-exposure prophylaxis |
| Q36974941 | Prophylactic efficacy of oral emtricitabine and tenofovir disoproxil fumarate combination therapy against a tenofovir-resistant simian/human immunodeficiency virus containing the K65R mutation in macaques |
| Q36306935 | Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir |
| Q35140323 | Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada |
| Q84509129 | Protective properties of non-nucleoside reverse transcriptase inhibitor (MC1220) incorporated into liposome against intravaginal challenge of Rhesus macaques with RT-SHIV |
| Q92213693 | Protocol for a longitudinal study to evaluate the use of tenofovir-based PrEP for safer conception and pregnancy among women in South Africa |
| Q35174468 | Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals |
| Q36379277 | Reduced inflammation and CD4 loss in acute SHIV infection during oral pre-exposure prophylaxis |
| Q28539563 | Residual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolution |
| Q34767070 | Rethinking prevention of HIV type 1 infection |
| Q36113575 | Retrocyclin RC-101 blocks HIV-1 transmission across cervical mucosa in an organ culture |
| Q37803317 | Role of nonhuman primates in the evaluation of candidate AIDS vaccines: an industry perspective |
| Q34072076 | Role of the pharmacist in pre-exposure chemoprophylaxis (PrEP) therapy for HIV prevention. |
| Q21558500 | Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers |
| Q36586078 | Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention |
| Q28533828 | Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial |
| Q40655103 | Sex frequency and sex planning among men who have sex with men in Bangkok, Thailand: implications for pre- and post-exposure prophylaxis against HIV infection. |
| Q36188256 | Sexual frequency and planning among at-risk men who have sex with men in the United States: implications for event-based intermittent pre-exposure prophylaxis |
| Q35697252 | Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study |
| Q37258298 | Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue |
| Q30858811 | Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial |
| Q40377358 | Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial |
| Q53769213 | Southern African guidelines on the safe use of pre-exposure prophylaxis in persons at risk of acquiring HIV-1 infection. |
| Q28260539 | Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS |
| Q90369517 | Statistical approaches to accelerate the development of long-acting antiretrovirals for HIV pre-exposure prophylaxis |
| Q35962036 | Stimulation of Liver X Receptor Has Potent Anti-HIV Effects in a Humanized Mouse Model of HIV Infection |
| Q30371157 | Surrogates of protection in repeated low-dose challenge experiments. |
| Q37793090 | Systemic Preexposure Prophylaxis for Human Immunodeficiency Virus Infection |
| Q28472590 | Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice |
| Q37061624 | Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis |
| Q30744184 | Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice |
| Q28477909 | T cell chemo-vaccination effects after repeated mucosal SHIV exposures and oral pre-exposure prophylaxis |
| Q33518390 | Targeting Trojan Horse leukocytes for HIV prevention |
| Q34034418 | Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission |
| Q22242692 | Tenofovir-based pre-exposure prophylaxis for HIV prevention |
| Q35902684 | The HIV Epidemic: High-Income Countries. |
| Q33681279 | The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications. |
| Q37511883 | The Promise of Antiretrovirals for HIV Prevention |
| Q33463290 | The effect of ongoing exposure dynamics in dose response relationships |
| Q38849706 | The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion |
| Q34982693 | The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques |
| Q35875723 | The promises and challenges of pre-exposure prophylaxis as part of the emerging paradigm of combination HIV prevention |
| Q34488291 | The role of exposure history on HIV acquisition: insights from repeated low-dose challenge studies |
| Q22241890 | The spread, treatment, and prevention of HIV-1: evolution of a global pandemic |
| Q35760180 | The use of preexposure treatments for HIV prophylaxis |
| Q28550108 | Topical Delivery of Tenofovir Disoproxil Fumarate and Emtricitabine from Pod-Intravaginal Rings Protects Macaques from Multiple SHIV Exposures |
| Q99241380 | Towards COVID-19 Prophylaxis: An AIDS Preclinical Research Perspective |
| Q59354852 | Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis |
| Q35558232 | Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya |
| Q36816377 | Use of antiretrovirals for HIV prevention: what do we know and what don't we know? |
| Q37614961 | Vaccines and microbicides preventing HIV-1, HSV-2, and HPV mucosal transmission |
| Q45356336 | Virological and molecular characterization of a simian human immunodeficiency virus (SHIV) encoding the envelope and reverse transcriptase genes from HIV-1. |
| Q88586767 | Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa |
| Q36294982 | Willingness to use pre-exposure prophylaxis for HIV prevention among female sex workers: a cross-sectional study in China |
| Q34030735 | Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials |
Search more.